![Connie Matsui](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Connie Matsui
Voorzitter bij
ARTELO BIOSCIENCES, INC.
Vermogen: 146 444 $ op 31-05-2026
Profiel
Mevrouw Connie L. Matsui is voorzitter bij Sutro Biopharma, Inc., voorzitter bij Artelo Biosciences, Inc., voorzitter bij Halozyme Therapeutics, Inc. en voorzitter bij Balboa Park Conservancy. Mevrouw Matsui was voorheen werkzaam als National President bij Girl Scouts of the USA, als Executive Vice President bij Biogen Idec New Ventures, Inc, als Senior Vice President bij IDEC Pharmaceuticals Corp, als Executive VP-Knowledge & Innovation Networks bij Biogen Idec, Inc, en als President & Chief Executive Officer bij The San Diego Foundation. Zij behaalde haar doctorale graad aan de Stanford University en een MBA aan de Stanford University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 05-06-2026 | 5.000 ( 0,03% ) | 146 150 $ | 31-05-2026 | |
| 20-02-2026 | 210 ( 0,01% ) | 294 $ | 31-05-2026 |
Actieve functies van Connie Matsui
| Bedrijven | Functie | Begin |
|---|---|---|
| ARTELO BIOSCIENCES, INC. | Voorzitter | 02-05-2017 |
| SUTRO BIOPHARMA, INC. | Voorzitter | 24-06-2019 |
Eerdere bekende functies van Connie Matsui
| Bedrijven | Functie | Einde |
|---|---|---|
| HALOZYME THERAPEUTICS, INC. | Voorzitter | - |
The San Diego Foundation
 The San Diego Foundation Miscellaneous Commercial ServicesCommercial Services Provides information about charitable giving and community needs | Algemeen Directeur | 01-05-2019 |
| BIOGEN INC. | Corporate Officer/Principal | 01-01-2009 |
Biogen Idec, Inc. (North Carolina)
 Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Corporate Officer/Principal | 01-01-2009 |
Biogen Idec New Ventures, Inc.
 Biogen Idec New Ventures, Inc. Investment ManagersFinance Biogen Idec New Ventures' strategy is to select investments in companies developing innovative human therapeutic products or technologies that will drive product discovery and development more efficiently. Their specific areas of interest are companies in Biogen Idec's current therapeutic areas of neurology, oncology and immunology/inflammation, but they also seek opportunities outside these areas that fit their strategies for longer-term growth. The firm invests at all stages of development; most of their investments are in early-stage companies. They also look for investment opportunities where they can leverage their parent's resources and scientific and development expertise to support these investments. | Corporate Officer/Principal | 31-03-2008 |
Opleiding van Connie Matsui
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
73
Eerstegraads connecties
11
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 11 |
|---|---|
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
The San Diego Foundation
The San Diego Foundation Miscellaneous Commercial ServicesCommercial Services Provides information about charitable giving and community needs | Commercial Services |
Halozyme Therapeutics, Inc.
 Halozyme Therapeutics, Inc. BiotechnologyHealth Technology Engages in the development and commercialization of recombinant human enzymes for the infertility, ophthalmology & oncology markets | Health Technology |
Sutro Biopharma, Inc.
 Sutro Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Develops new products in protein vaccines and therapeutics | Health Technology |
Artelo Biosciences, Inc.
 Artelo Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company that develops endocannabinoid system modulating therapeutics | Health Technology |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
IDEC Pharmaceuticals Corp.
 IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes targeted immunotherapies for the treatment of cancer and autoimmune diseases | Health Technology |
Biogen Idec New Ventures, Inc.
Biogen Idec New Ventures, Inc. Investment ManagersFinance Biogen Idec New Ventures' strategy is to select investments in companies developing innovative human therapeutic products or technologies that will drive product discovery and development more efficiently. Their specific areas of interest are companies in Biogen Idec's current therapeutic areas of neurology, oncology and immunology/inflammation, but they also seek opportunities outside these areas that fit their strategies for longer-term growth. The firm invests at all stages of development; most of their investments are in early-stage companies. They also look for investment opportunities where they can leverage their parent's resources and scientific and development expertise to support these investments. | Finance |
Biogen Idec, Inc. (North Carolina)
Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Girl Scouts of the USA
 Girl Scouts of the USA Miscellaneous Commercial ServicesCommercial Services Helps to build character and skills for girls | Commercial Services |
Balboa Park Conservancy
 Balboa Park Conservancy Miscellaneous Commercial ServicesCommercial Services Provides advocacy services | Commercial Services |
